311 related articles for article (PubMed ID: 12721508)
1. Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas.
Colao A; Filippella M; Di Somma C; Manzi S; Rota F; Pivonello R; Gaccione M; De Rosa M; Lombardi G
Endocrine; 2003 Apr; 20(3):279-83. PubMed ID: 12721508
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
3. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
4. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
[TBL] [Abstract][Full Text] [Related]
5. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
7. The role of octreotide (Sandostatin) in non-growth hormone-, non-thyroid-stimulating hormone-, and non-prolactin-secreting adenomas.
Warnet A
Metabolism; 1992 Sep; 41(9 Suppl 2):59-61. PubMed ID: 1325596
[TBL] [Abstract][Full Text] [Related]
8. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
Lucas T; Astorga R; Catalá M;
Clin Endocrinol (Oxf); 2003 Apr; 58(4):471-81. PubMed ID: 12641631
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
Florio T; Thellung S; Corsaro A; Bocca L; Arena S; Pattarozzi A; Villa V; Massa A; Diana F; Schettini D; Barbieri F; Ravetti JL; Spaziante R; Giusti M; Schettini G
Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513
[TBL] [Abstract][Full Text] [Related]
10. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
Gancel A; Vuillermet P; Legrand A; Catus F; Thomas F; Kuhn JM
Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308
[TBL] [Abstract][Full Text] [Related]
11. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
12. Plasma alpha-subunit levels during the treatment of pituitary adenomas with the somatostatin analog (SMS 201-995).
Sassolas G; Serusclat P; Claustrat B; Trouillas J; Merabet S; Cohen R; Souquet JC
Horm Res; 1988; 29(2-3):124-8. PubMed ID: 2456975
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
[TBL] [Abstract][Full Text] [Related]
15. [The role of somatostatin analogues in the treatment of hypophyseal adenomas].
Losa M; Mortini P; Giovanelli M
Minerva Endocrinol; 2003 Mar; 28(1):39-51. PubMed ID: 12621362
[TBL] [Abstract][Full Text] [Related]
16. Structure and function of somatostatin receptors in growth hormone control.
Shimon I; Melmed S
J Endocrinol; 1997 Oct; 155 Suppl 1():S3-6; discussion S7-8. PubMed ID: 9389989
[TBL] [Abstract][Full Text] [Related]
17. [Somatostatin analogs in the clinical management of pituitary neoplasms].
Colao A; Dorato M; Pulcrano M; Rossi FW; Auriemma RS; Lombardi G; Lastoria S
Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
19. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
Gatto F; Barbieri F; Gatti M; Wurth R; Schulz S; Ravetti JL; Zona G; Culler MD; Saveanu A; Giusti M; Minuto F; Hofland LJ; Ferone D; Florio T
Clin Endocrinol (Oxf); 2012 Mar; 76(3):407-14. PubMed ID: 21848909
[TBL] [Abstract][Full Text] [Related]
20. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Saveanu A; Jaquet P; Brue T; Barlier A
Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
